AstraZeneca’s new weight-loss pill, AZD5004, shows promise in early trials with tolerable side effects, advancing to Phase II studies focused on reducing obesity.
AstraZeneca reported on Monday that its experimental weight-loss pill, AZD5004, licensed from China's Eccogene for up to $2 billion, was found safe and tolerable in an early-stage trial.
The study, which included 72 participants who were either healthy or had type 2 diabetes, showed side effects consistent with other GLP-1 drugs, such as nausea and vomiting. Based on these findings, AstraZeneca has advanced AZD5004 to Phase II trials focused on weight reduction in overweight and obese individuals, with completion expected by late 2025.
Unlike injectable treatments from competitors Eli Lilly and Novo Nordisk, AZD5004 is a small molecule pill that can be combined with other medications and taken with or without food, offering potential advantages for patients with additional health conditions.
AstraZeneca also shared early-stage data on other obesity drugs, AZD6234 and AZD9550, which target different hunger-related hormones and will undergo further Phase II testing through 2026.
Meanwhile, Viking Therapeutics released early trial results for its own oral obesity drug, which briefly boosted its stock before a decline.
Ukrainian, U.S. and Russian officials are meeting in Abu Dhabi for their first-ever trilateral talks on the nearly four-year-long war in Ukraine....
UK Prime Minister Keir Starmer has accused U.S. President Donald Trump of making “insulting and frankly appalling” remarks about Nato forces in Af...
Tokyo Electric Power Company (TEPCO) has suspended operations at the Kashiwazaki-Kariwa nuclear power plant in Japan, just a day after a reactor was b...
Italy’s legendary couturier Valentino was laid to rest in Rome on Friday (23 January), drawing designers, actors and industry leaders to a ceremony ...
The claim that U.S. President Donald Trump's intervention stopped the execution of 800 detainees is "completely false", said prosecutor-general of Ira...
A groundbreaking study presented at ASCO reveals that AstraZeneca’s experimental pill camizestrant, when used based on blood test results, can halve the risk of breast cancer progression or death—potentially reshaping treatment for patients with hormone receptor-positive, HER2-negative breast cancer
AstraZeneca, opens new tab said it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year.
President Donald Trump said on Thursday that the United States has an "armada" heading toward Iran but hoped he would not have to use it, as he renewed warnings to Tehran against killing protesters or restarting its nuclear programme.
Russian President Vladimir Putin said on Wednesday that Moscow could pay $1 billion from Russian assets frozen abroad to secure permanent membership in President Donald Trump’s proposed ‘Board of Peace’.
A commuter train collided with a construction crane in southeastern Spain on Thursday (22 January), injuring several passengers, days after a high-speed rail disaster in Andalusia killed at least 43 people.
Turkish President Recep Tayyip Erdoğan has told his Iranian counterpart Masoud Pezeshkian that Türkiye opposes any form of foreign intervention in Iran, as protests and economic pressures continue to fuel tensions in the Islamic republic.
President Donald Trump says he has agreed a "framework" for a Greenland deal with NATO.
Researchers in China said they have developed a “smart living glue” made from engineered gut bacteria that can detect internal bleeding and help repair intestinal damage, offering a targeted new approach to treating inflammatory bowel disease.
Mongolia has introduced a new decree to strengthen traditional Mongolian medicine and expand its international profile.
Save the Children has pledged to expand maternal and child health services across Afghanistan after its new country director met the country’s public health minister in Kabul on Wednesday.
China has announced plans to fully cover childbirth-related costs for families as authorities move to incentivise young couples to have more children.
World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus said on Thursday that he still hopes the U.S. administration will reconsider its decision to withdraw from the organisation next month, warning that its exit would be a loss for the world.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment